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Abstract
The recently released National Public Health Action Plan for the Detection, Prevention, and 
Management of Infertility calls for better access to high-quality infertility services and improved 
safety of fertility treatments. Both assisted reproductive technology (ART) and non-ART fertility 
treatments have allowed millions of patients worldwide to overcome infertility—a disease of the 
reproductive system and important public health issue. However, there are substantial disparities in 
access to effective treatments in the United States, largely attributable to high out-of-pocket costs, 
especially for ART. Moreover, the outcomes of fertility treatments are often complicated by the 
large proportion of multiple births with substantial health risks for both neonates and mothers. 
Prevention of multiple births is difficult during non-ART fertility treatments but can be effective 
with single-embryo transfer during ART. Several U.S. states have enacted legislative mandates that 
require private insurers to cover some portion of the costs associated with fertility treatments and 
thus reduce the financial pressure to transfer multiple embryos during ART. Although studies have 
shown that insurance coverage reduces per-cycle multiple births to a certain degree, states with 
insurance mandates have more ART-related multiple births attributable to substantially larger 
number of ART-conceived neonates. Experience from other countries shows that access to ART 
can be improved without concomitant increases in multiple births by providing reimbursement for 
ART in combination with restrictions on the number of embryos transferred per cycle. Such 
approaches may or may not be successful in the United States with its unique and complex health 
care system.
Infertility is a disease of the reproductive system and important public health issue.1 To 
better understand public health implications of infertility, the Centers for Disease Control 
and Prevention recently released its first National Public Health Action Plan for the 
Detection, Prevention, and Management of Infertility.1 In addition to promoting strategies 
for the prevention and early detection of infertility, the plan calls for eliminating disparities 
in access to high-quality infertility services and improving safety of fertility treatments. 
Assisted reproductive technology (ART) (defined as fertility treatments in which eggs or 
embryos are handled in the laboratory with the purpose of establishing a pregnancy, such as 
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in vitro fertilization with or without intracytoplasmic sperm injection) and non-ART fertility 
treatments (defined as fertility drugs that induce or enhance ovulation in women and are 
used with timed intercourse or intrauterine insemination but with no intention of performing 
ART) have been used to help millions of people all over the world overcome infertility. 
Since the 1960s when non-ART fertility treatments were first introduced, and especially 
after the first ART birth in 1978, the field of fertility treatments has experienced 
unprecedented growth, which is expected to continue because of the increasing availability 
of these treatments and growing demand resulting from delayed childbearing in developed 
nations. As fertility treatments play a larger role in human reproduction, their effect on 
demographics and public health is likely to expand. In the United States, the effects of 
fertility treatments on public health are associated with several factors, including disparities 
in access to more effective treatment options and suboptimal maternal and child health 
outcomes, primarily related to the large proportion of multiple births.1
Although many non-ART fertility treatments are relatively affordable or covered by 
insurance, they often lead to multiple births resulting from the limited ability to predict or 
control the number of fertilized oocytes and inadequate use of strategies to minimize 
multiple births. Multiple births are especially common when gonadotropin preparations are 
used in non-ART cycles.2 On the other hand, ART is often associated with high out-of-
pocket costs as a result of limited or lack of insurance coverage, which can make these 
treatments unaffordable for most U.S. couples affected by infertility. As such, treatment 
decisions can be influenced by financial incentives. For example, some couples may choose 
or be required to undergo multiple rounds of less costly non-ART fertility treatments. 
Likewise, couples may be motivated to transfer multiple embryos per ART cycle to 
maximize their chances of “success” and avoid another treatment. Notably, many also 
express a preference for twins, either underestimating or ignoring the higher risks.
Unlike all ART cycles that are annually reported to the Centers for Disease Control and 
Prevention’s National ART Surveillance System, there is no national reporting of non-ART 
fertility treatments. As estimated in a recent study, in 2011, ART and non-ART fertility 
treatments contributed to 36% of all twin births (17% and 19%, respectively) and 77% of all 
triplet and higher order multiple births in the United States (32% and 45%, respectively).3 
Although non-ART treatments contribute to a larger proportion of multiple births in the 
United States than ART, the ability to prevent iatrogenic multiple births is much higher with 
ART, in which single-embryo transfer among eligible patients leaves almost no chance for 
multiple gestation.4,5
Access to ART varies around the globe and depends on many factors, including availability 
of services, religious or ethical considerations as well as affordability of treatment, which 
takes into account procedure cost, people’s disposable income, and level of subsidization. 
The average cost of one fresh ART cycle in the United States ($13,048 in 2006 U.S. dollars) 
can be more than 46% of annual disposable income, resulting in greater net cost for U.S. 
patients than patients in other developed countries.6 As a result, only people with high 
socioeconomic status or adequate insurance can afford the needed treatment, leading to 
substantial disparities in access to ART. According to the Centers for Disease Control and 
Prevention’s National Survey of Family Growth, non-Hispanic black women of reproductive 
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age are more than 80% more likely to report infertility than non-Hispanic white women,7 but 
they are more than 20% less likely to ever receive any infertility services.8
Another consequence of the high out-of-pocket costs of ART is the financial incentive to 
transfer multiple embryos to increase the chance of live birth, a practice that increases 
multiple births with substantial risks for both neonates and their mothers. Regardless of the 
cause of multiple births, neonates born as multiples are more likely to be preterm and have 
low birth weight, and they are at higher risk for morbidity, including cerebral palsy and 
autism spectrum disorders. Twins have a 6-fold higher chance of neonatal death than 
singletons, and triplets have a 14-fold higher chance. Women carrying multiples are at 
higher risk for cesarean delivery, gestational hypertension, preeclampsia, gestational 
diabetes, hemorrhage, maternal hospital admission, and mental health dysfunctions. Because 
almost half of children conceived by ART in the United States are born in multiple 
gestations,9 overall health risks for these children and their mothers are substantially higher 
than among the general population. Although there is ongoing debate whether worse health 
outcomes of children conceived by ART result from underlying factors associated with 
parental infertility or treatment itself, iatrogenic multiple births resulting from the 
unnecessary transfer of more than one embryo undoubtedly play a major role.3
Because reduced financial pressure is thought to increase the practice of elective single-
embryo transfer and, subsequently, lead to healthy singleton births, insurance coverage of 
ART has been touted as a mechanism to improve outcomes. In the United States, 15 states 
have enacted legislative mandates (the most recent one was enacted in Connecticut in 2005) 
with wide variations in restrictions and exceptions that require insurers to cover some 
portion of the costs associated with fertility treatments.9 Although studies have shown that 
insurance coverage for ART (currently mandated in eight states) is associated with fewer 
embryos transferred per cycle and reduces per-cycle multiple births to a certain degree,10–13 
the expectation that insurance coverage will solve the problem of ART-related multiple 
births has not been realized. To the contrary, states with insurance mandates requiring ART 
coverage tend to have more ART-related multiple births than other states.9 The reason is that 
the modest increase in single-embryo transfers and corresponding decrease in multiple births 
are offset by a dramatic increase in ART use, because ART is more affordable in states with 
the most comprehensive insurance mandates. The substantially larger number of neonates 
conceived by ART in these states leads to more ART-related multiple births (Fig. 1). To the 
best of our knowledge, none of the states with mandated insurance coverage for ART linked 
such coverage with limits on the number of embryos transferred per cycle, although there is 
anecdotal evidence that some insurers have introduced their own restrictions on number of 
embryos transferred per cycle. In addition, because some mandates require a certain number 
of non-ART cycles before ART-related benefits can be accessed, states with insurance 
mandates may have a large number of multiple births after non-ART fertility treatments.
What is the best way to balance expanded access to expensive but highly effective 
technology needed by thousands of couples affected by infertility in the United States with 
the need to promote the health of children conceived by ART? Experience from several 
countries shows that providing reimbursement for ART in combination with restrictions on 
the number of embryos transferred can address both issues without significant reductions in 
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live birth rates.14–16 Policies where ART coverage is contingent on limitations on the 
number of transferred embryos have resulted in a dramatic increase in the proportion of ART 
cycles involving single embryos as well as a corresponding decrease in the proportion of 
multiple births: 54% reduction of multiple births in Australia (from 19% to 9%), 59% 
reduction in Belgium (from 27% to 11%), and 84% reduction in Sweden (from 35% to 6%). 
Whether these approaches will work in the United States, given the country’s unique and 
complex health care system, is unknown.
As more and more people are turning to fertility treatments to achieve their reproductive 
goals, it is important to ensure that such treatments are accessible and safe. In the context of 
non-ART fertility treatments, it has been suggested that low-dose gonadotropin protocols 
may reduce the risk of multiple births.17,18 For some patients, faster transition to more 
effective fertility treatment options such as ART may be beneficial because time to 
pregnancy is reduced and exposure to ovulation induction is minimized.18,19 However, 
because little is known about effectiveness or safety of non-ART fertility treatments, 
systematic collection of national data on the use and outcomes of ovulation induction and 
ovarian stimulation is an important first step that can lead to the development of better 
treatment practices and alleviate their adverse outcomes. More economic analyses are 
needed to show whether insurance coverage for ART, coupled with safer ART practices, can 
improve health equity and reduce health care costs associated with iatrogenic multiple 
births. Development of prediction models can help patients and health care providers to 
determine the best time for transitioning from one protocol to another and select the safest 
and most cost-effective treatment algorithms.20 The importance of new approaches to 
educate couples affected by infertility about the risks of multiple births and the benefits of 
building their families one newborn at a time cannot be overstated. Well-designed 
comparative studies that use data from countries with different ART policies may also be 
useful for studying the effect of these policies on access to ART and its outcomes. A U.S.-
based study that assesses reproductive outcomes among women covered by health insurance 
plans that link reimbursement for ART with limitations on the number of embryos 
transferred would provide important information on the acceptability and feasibility of such 
an approach in this country. Such a study will require broad collaboration among federal and 
state public health agencies, professional societies, consumer groups, and insurance 
providers.
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Fig. 1. 
Proportion of singletons and multiples among neonates conceived by assisted reproductive 
technology (ART) and relative proportion of neonates conceived by ART among all neonates 
born, by ART insurance mandate status, United States, 2013. The proportion of multiples 
among ART-conceived neonates in states without an ART insurance mandate (46.2%) is 
approximately 6% higher than that in states with an ART insurance mandate (43.6%). The 
size of the pie charts shows the relative proportion of neonates conceived by ART among all 
neonates born. The proportion of ART-conceived neonates among all neonates born in states 
without an ART insurance mandate (1.3%) is 123% lower than that in states with an ART 
insurance mandate (2.9%). Data from National ART Surveillance System, 2013 (http://
www.cdc.gov/art/index.html).
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